QA: Renovorx Inc in us_pharma/2024

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001574094_2025_Renovorx_Inc.pdf

Logs

warning Missing logo subcommand.report {}
info NetIncome node detected by revenue/expenses heuristic input.sec.calculation_linkbase.edgar_model_mapping {'net_inc_node': 'OperatingIncomeLoss'}

Graph

Absolute values for 0001574094, Renovorx Inc

  xvar xval
0 AssetsCurrent 7,828,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 12,000
3 remainder_Assets 278,000
4 LiabilitiesCurrent 1,909,000
5 LiabilitiesNoncurrent 212,000
6 remainder_Liabilities 1,519,000
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 4,252,730
9 ResearchAndDevelopmentExpense 6,342,801
10 remainder_Expenses 0
11 remainder_Revenues 43,000
12 remainder_NetIncome 366,088
13 remainder_ComprehensiveNetIncome 25,644
  yvar yval
0 Assets 8,118,000
1 Liabilities 3,640,000
2 Expenses 10,595,531
3 Revenues 43,000
4 StockholdersEquity 4,478,000
5 NetIncome -10,186,443
6 ComprehensiveNetIncome -10,173,621
7 BaseVar 11,394,132
8 EconomicCapitalRatiobeforeLimitedLiability -0.0700
9 EconomicCapitalRatio 1.41

Edgar->Model Mapping

Feature Distribution

Change over Time